Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers

By Sendurai A Mani, Jing Yang, M. Brooks, Gunda Schwaninger, A. Zhou, N. Miura, J. Kutok, Kimberly A. Hartwell, A. Richardson, R. Weinberg. Proceedings of the National Academy of Sciences of the United States of America, 2007

600 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/d66c467a9e89beb931ce56e7d16919b7260c2534

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. R. Weinberg
2. Jing Yang
3. M. Nieto
4. A. Cano
5. G. Moreno-Bueno
6. J. Tsai
7. Eric S. Lander
8. Piyush B. Gupta

In Oncology

1. R. Weinberg
2. Jing Yang
3. M. Nieto
4. J. Tsai
5. Jeffrey M. Rosen
6. Eric S. Lander
7. A. Cano
8. G. Moreno-Bueno

Citations in the corpus

• Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. (2008, background): “tors, FOXC2 (Mani et al., 2007) and Goosecoid (Hartwell et al.”
• Transcriptional regulation of cell polarity in EMT and cancer (2008, background): “Most of the present knowledge regarding the regulation of EMT has come from studies of the mechanisms underlying E-cadherin loss, which has led to the identification of several transcriptional repressors including members of the Snail superfamily, SNAI1 (previously known as Snail) and SNAI2 (previou”
• Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy (2020, background): “EMT is linked not only to increased metastasis (Yang et al., 2004; Mani et al., 2007; Ocana et al., 2012; Stankic et al., 2013) but also to chemoresistance (Singh and Settleman, 2010; Haslehurst et al., 2012; Ren et al., Frontiers in Molecular Biosciences | www.frontiersin.org 4 January 2020 |…”
• Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes (2010, background): “The closely related FOXC2TF is known to play a key role in inducing an EMT, promoting metastasis and to be associated with aggressive basal-like breast cancers as studied using immunohistochemistry methods (14).”
• The epithelial-mesenchymal transition generates cells with properties of stem cells. (2008, unknown): “…confer malignant traits, such as motility, invasiveness, and resistance to apoptosis, on neoplastic cells (Cheng et al., 2007; Comijn et al., 2001; Hartwell et al., 2006; Huber et al., 2005; Mani et al., 2007; Oft et al., 2002; Peinado et al., 2007; Savagner et al., 2005; Yang et al., 2004, 2006).”
• Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features (2009, background): “We therefore examined a number of mesenchymal markers described in a literature review (20) and found that, as predicted, a number of these markers were elevated (FN1, SNAI2, VIM, FOXC2, MMP2, and MMP3) or diminished (CDH1 and DSP) at the RNA level in the cancer MSs vs.”
• Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. (2008, unknown): “Moreover, the mesenchymal transcription factor FOXC2, which promotes EMT and metastasis in vivo , has also been associated with basallike cancers (46).”
• Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. (2012, background): “The EMT program is orchestrated through a network of transcription factors, including Twist1 (Yang et al., 2004), Snail1/2 (Batlle et al., 2000; Cano et al., 2000; Hajra et al., 2002), Zeb1/2 (Comijn et al., 2001; Eger et al., 2005), and FOXC2 (Mani et al., 2007).”